Back to results
US 2023/0405093 A1Published application
Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by fabry disease
AssigneeHanmi Pharm. Co., Ltd.
InventorsJae Hyuk CHOI, Jin Young KIM, Cho Rong PARK, Sang Yun KIM, Jeong A KIM, Doo Seo JANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to use of a fusion protein of a therapeutic enzyme and an immunoglobulin Fc region in the prevention or improvement of renal diseases caused by or accompanied by Fabry disease.
Claims18
A method for preventing or treating renal diseases caused by or accompanied by Fabry disease, comprising administering a pharmaceutical composition to a patient in need thereof, wherein the pharmaceutical composition comprises an enzyme fusion protein represented by the following Chemical Formula 1:
- wherein X and X′ are each alpha-galactosidase;
- L and L′ are linkers, each independently the same or a different kind of linker;
- F is one polypeptide chain of an immunoglobulin Fc region;
- ∥ is a covalent bond;
- and
- :
- is a covalent or non-covalent bond.
4 more elements
Dependencies are inferred from the claim text.